Investigation on design of stable etoposide-loaded PEG-PCL micelles: Effect of molecular weight of PEG-PCL diblock copolymer on the in vitro and in vivo performance of micelles

Drug Delivery

Volumn 19, Issue 3, 2012, Pages 155-167

  Ukawala, Mukesh ^a   Rajyaguru, Tushar ^a   Chaudhari, Kiran ^a   Manjappa, A S ^a   Pimple, Smita ^a   Babbar, A K ^b   Mathur, Rashi ^b   Mishra, A K ^b   Murthy, R S R ^a,c  

^a M S UNIVERSITY OF BARODA   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^c ISF COLLEGE OF PHARMACY   (India)

Author keywords

etoposide; fixed aqueous layer thickness; hemolysis; Micelles; nanoprecipitation; PEG surface density; polymeric drug delivery system

Indexed keywords

COPOLYMER; ETOPOSIDE; MACROGOL; POLYCAPROLACTONE; SERUM ALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION (PARAMETERS); DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; EHRLICH ASCITES TUMOR; FEMALE; HEMOLYSIS; IN VITRO STUDY; IN VIVO CULTURE; MICELLE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SURFACE PROPERTY; SYNTHESIS; THICKNESS; X RAY DIFFRACTION; ZETA POTENTIAL;

ANIMALS; CARCINOMA, EHRLICH TUMOR; DRUG DESIGN; DRUG STABILITY; ETHYLENE OXIDE; ETOPOSIDE; FEMALE; LACTONES; MICE; MICE, INBRED BALB C; MICELLES; MOLECULAR WEIGHT; TREATMENT OUTCOME; X-RAY DIFFRACTION;

EID: 84858670525     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2012.657721     Document Type: Article

References (49)

1. Aita P, Robieux I, Sorio R, Tumolo S, Corona G, Cannizzaro R et al. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol 1999;43:287-294. (Pubitemid 29075885)
2. Aliabadi HM, Elhasi S, Mahmud A, Gulamhusein R, Mahdipoor P, Lavasanifar A. Encapsulation of hydrophobic drugs in polymeric micelles through co-solvent evaporation: the effect of solvent composition on micellar properties and drug loading. Int J Pharm 2007;329:158-165. (Pubitemid 44937525)
3. Aliabadi HM, Mahmud A, Sharifabadi AD, Lavasanifar A. Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A. J Control Release 2005;104:301-311. (Pubitemid 40724931)
4. Allen C, Eisenberg A, Mrsic J, Maysinger D. PCL-b-PEO micelles as a delivery vehicle for FK506: assessment of a functional recovery of crushed peripheral nerve. Drug Deliv 2000;7:139-145.
5. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Livaniou E, Evangelatos G et al. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int J Pharm 2003;259:115-127. (Pubitemid 36638559)
6. Babbar A, Kashyap R, Chauhan UP. A convenient method for the preparation of 99mTc-labelled pentavalent DMSA and its evaluation as a tumour imaging agent. J Nucl Biol Med 1991;35:100-104.
7. Bae YH, Yin H. Stability issues of polymeric micelles. J Control Release 2008;131:2-4.
8. Bazile D, Prud'homme C, Bassoullet MT, Marlard M, Spenlehauer G, Veillard M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 1995;84:493-498.
9. Burt HM, Zhang X, Toleikis P, Embree L, Hunter WL. (1999). Development of copolymers of poly(DLlactide) methoxypolyethylene glycol as micellar carriers of paclitaxel. Colloids Surf B 16:161-171. (Pubitemid 29486803)
10. Choi C, Chae SY, Kim T, Kweon JK, Cho CS, Jang M, Nah J. (2006). Synthesis physicochemical characterization of amphiphilic block copolymer self-aggregates formed by poly(ethylene glycol)-block-poly(ε-caprolactone). J Appl Polym Sci 99:3520-3527.
11. Forrest ML, Won CY, Malick AW, Kwon GS. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(epsiloncaprolactone) micelles. J Control Release 2006;110:370-377. (Pubitemid 41827491)
12. Forrest ML, Yáñez JA, Remsberg CM, Ohgami Y, Kwon GS, Davies NM. Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity. Pharm Res 2008;25:194-206.
13. Gadelle F, Koros WJ, Schechter RS. (1995). Solubilization of aromatic solutes in block copolymers. Macromolecules, 28, 4883-92.
14. Ge H, Hu Y, Jiang X, Cheng D, Yuan Y, Bi H et al. Preparation, characterization, and drug release behaviors of drug nimodipine-loaded poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) amphiphilic triblock copolymer micelles. J Pharm Sci 2002;91:1463-1473. (Pubitemid 34633962)
15. Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 2000;18:301-313. (Pubitemid 30479870)
16. Halder KK, Mandal B, Debnath MC, Bera H, Ghosh LK, Gupta BK. Chloramphenicol-incorporated poly lactide-co-glycolide (PLGA) nanoparticles: formulation, characterization, technetium-99m labeling and biodistribution studies. J Drug Target 2008;16:311-320. (Pubitemid 351622361)
17. Hu Y, Xie J, Tong YW, Wang CH. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J Control Release 2007;118:7-17. (Pubitemid 46283099)
18. Jeon SI, Lee JH, Andrade JD, De Gennes PG. (1991). Protein-surface interaction in the presence of polyethylene oxide. J Colloids Interface Sci 142:149-158.
19. Kim MS, Hyun H, Cho YH, Seo KS, Jang WY, Kim SK, Khang G, Lee HB. (2005). Preparation of methoxy poly(ethyleneglycol)-block poly(caprolactone) via activated monomer mechanism examination of micellar characterization. Pol Bull 55:149-156. (Pubitemid 41241773)
20. Kim MS, Seo KS, Khang G, Cho SH, Lee HB. Preparation of poly(ethylene glycol)-block-poly(caprolactone) copolymers and their applications as thermo-sensitive materials. J Biomed Mater Res A 2004;70:154-158. (Pubitemid 38849823)
21. Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008;108:241-250. (Pubitemid 351311357)
22. Letchford K, Liggins R, Burt H. Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: theoretical and experimental data and correlations. J Pharm Sci 2008;97:1179-1190.
23. Letchford K, Liggins R, Wasan KM, Burt H. In vitro human plasma distribution of nanoparticulate paclitaxel is dependent on the physicochemical properties of poly(ethylene glycol)-blockpoly(caprolactone) nanoparticles. Eur J Pharm Biopharm 2009;71:196-206.
24. Lin WJ, Wang CL, Chen YC. Comparison of two pegylated copolymeric micelles and their potential as drug carriers. Drug Deliv 2005;12:223-227.
25. Liu J, Zeng F, Allen C. Influence of serum protein on polycarbonate-based copolymer micelles as a delivery system for a hydrophobic anti-cancer agent. J Control Release 2005;103:481-497. (Pubitemid 40342543)
26. Liu J, Zeng F, Allen C. In vivo fate of unimers and micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administration. Eur J Pharm Biopharm 2007;65:309-319.
27. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 2004;91:1775-1781. (Pubitemid 39664964)
28. Mishra P, Babbar A, Chauhan UP. A rapid instant thin layer chromatographic procedure for determining radiochemical purity of 99Tcm-IDA agents. Nucl Med Commun 1991;12:467-469.
29. Molavi O, Ma Z, Mahmud A, Alshamsan A, Samuel J, Lai R et al. Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors. Int J Pharm 2008;347:118-127. (Pubitemid 350180319)
30. Peracchia MT, Vauthier C, Passirani C, Couvreur P, Labarre D. Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles. Life Sci 1997;61:749-761. (Pubitemid 27315736)
31. Riley T, Govender T, Stolnik S, Xiong CD, Garnett MC, Illum L, Davis SS. (1999). Colloidal stability drug incorporation aspects of micellar-like PLA-PEG nanoparticles. Colloids Surf B 16:147-59. (Pubitemid 29486802)
32. Sadzuka Y, Nakade A, Hirama R, Miyagishima A, Nozawa Y, Hirota S et al. Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome. Int J Pharm 2002;238:171-180. (Pubitemid 34457886)
33. Sadzuka Y, Sugiyama I, Tsuruda T, Sonobe T. Characterization and cytotoxicity of mixed polyethyleneglycol modified liposomes containing doxorubicin. Int J Pharm 2006;312:83-89.
34. Savic R, Azzam T, Eisenberg A, Maysinger D. Assessment of the integrity of poly(caprolactone)-b-poly(ethylene oxide) micelles under biological conditions: a fluorogenic-based approach. Langmuir 2006;22:3570-3578. (Pubitemid 43672524)
35. Shen C, Guo S, Lu C. (2007). Degradation behaviors of star-shaped poly(ethylene glycol)-poly (ε-caprolactone) nanoparticles in aqueous solution. Polym Degrad Stabil 92:1891-98. (Pubitemid 47531870)
36. Shi B, Fang C, You MX, Zhang Y, Fu S, Pei YY. (2005). Stealth MePEG-PCL micelles: effects of polymer composition on micelle physicochemical characteristics, in vitro drug release, in vivo pharmacokinetics in rats biodistribution in S180 tumor bearing mice. Colloid Polym Sci 283:954-67. (Pubitemid 40796438)
37. Snehalatha M, Venugopal K, Saha RN, Babbar AK, Sharma RK. Etoposide loaded PLGA and PCL nanoparticles II: biodistribution and pharmacokinetics after radiolabeling with Tc-99m. Drug Deliv 2008;15:277-287.
38. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:1-20. (Pubitemid 32144788)
39. Stolnik S, Heald CR, Neal J, Garnett MC, Davis SS, Illum L et al. Polylactide-poly(ethylene glycol) micellar-like particles as potential drug carriers: production, colloidal properties and biological performance. J Drug Target 2001;9:361-378. (Pubitemid 33094555)
40. Stolnik S, Illum L, Davis SS. (1995). Long circulating microparticulate drug carriers. Adv Drug Deliv Rev 16:195-214.
41. Sutton D, Wang S, Nasongkla N, Gao J, Dormidontova EE. Doxorubicin and beta-lapachone release and interaction with micellar core materials: experiment and modeling. Exp Biol Med (Maywood) 2007;232:1090-1099. (Pubitemid 47358192)
42. Vangeyte P, Gautier S, Jerome R. (2004). About the methods of preparation of poly(ethylene oxide)-b-poly(ε-caprolactone) nanoparticles in water analysis by dynamic light scattering. Colloids Surf A: Physiochem Eng Aspects 242:203-211. (Pubitemid 38981591)
43. Wei X, Gong C, Shi S, Fu S, Men K, Zeng S et al. Self-assembled honokiol-loaded micelles based on poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) copolymer. Int J Pharm 2009;369:170-175.
44. Xiong MP, Yáñez JA, Remsberg CM, Ohgami Y, Kwon GS, Davies NM et al. Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats. J Control Release 2008;129:33-40.
45. Yadav AK, Mishra P, Jain S, Mishra P, Mishra AK, Agrawal GP. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin. J Drug Target 2008;16:464-478. (Pubitemid 352015815)
46. Yáñez JA, Forrest ML, Ohgami Y, Kwon GS, Davies NM. Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon- caprolactone) micelles of rapamycin. Cancer Chemother Pharmacol 2008;61:133-144. (Pubitemid 47512635)
47. Yang A, Yang L, Liu W, Li Z, Xu H, Yang X. Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation. Int J Pharm 2007;331:123-132. (Pubitemid 46176498)
48. Zastre J, Jackson JK, Wong W, Burt HM. Methoxypolyethylene glycol-block-polycaprolactone diblock copolymers reduce P-glycoprotein efflux in the absence of a membrane fluidization effect while stimulating P-glycoprotein ATPase activity. J Pharm Sci 2007;96:864-875. (Pubitemid 46657874)
49. Zhang L, Hu Y, Jiang X, Yang C, Lu W, Yang YH. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly (caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J Control Release 2004;96:135-148. (Pubitemid 38438496)